Sanofi announces FDA approval of Auvi-Q
Global healthcare leader, Sanofi has announced that the US FDA has approved Auvi-Q for the emergency treatment of life-threatening allergic reactions in people who are at risk for, or have a history of, anaphylaxis. Sanofi US licensed the North American commercialization rights to Auvi-Q from Intelliject, Inc., which has retained commercialization rights for the rest of the world.
Auvi-Q is the first and only compact epinephrine auto-injector, which has audio and visual cues that guide patients and caregivers step-by-step through the injection process.
“As a company committed to patient-centered care, our focus is on creating innovative solutions that make a difference in the lives of people. Auvi-Q delivers on this by offering a state-of-the-art epinephrine auto-injector device that addresses the needs of patients at risk for life-threatening allergic reactions and their caregivers.”
Anne Whitaker, President, North America Pharmaceuticals, Sanofi US.
Anaphylaxis is listed as a rare disease by the Office of Rare Diseases (ORD) of the National Institutes of Health (NIH), which means that the condition affects less than 200,000 people in the US population. However, according to the 2010 American Academy of Allergy, Asthma &, Immunology Practice Parameters, up to six million Americans may be at risk for anaphylaxis. This shows that the precise incidence of anaphylaxis is unknown and is most likely underreported.
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.